7,064 Shares in Cassava Sciences, Inc. (NASDAQ:SAVA) Bought by Independent Advisor Alliance

Independent Advisor Alliance purchased a new position in shares of Cassava Sciences, Inc. (NASDAQ:SAVA) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,064 shares of the company’s stock, valued at approximately $208,000.

Several other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. grew its stake in Cassava Sciences by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 2,356,480 shares of the company’s stock valued at $47,813,000 after purchasing an additional 31,854 shares during the period. CANADA LIFE ASSURANCE Co grew its stake in Cassava Sciences by 146.7% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 9,408 shares of the company’s stock valued at $191,000 after purchasing an additional 5,594 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Cassava Sciences by 4.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,327 shares of the company’s stock valued at $636,000 after purchasing an additional 1,456 shares during the period. Brookstone Capital Management grew its stake in Cassava Sciences by 6.0% in the 2nd quarter. Brookstone Capital Management now owns 17,753 shares of the company’s stock valued at $219,000 after purchasing an additional 1,000 shares during the period. Finally, Essex LLC grew its stake in Cassava Sciences by 9.2% in the 2nd quarter. Essex LLC now owns 55,318 shares of the company’s stock valued at $683,000 after purchasing an additional 4,644 shares during the period. Institutional investors own 38.05% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Rodman & Renshaw reiterated a “buy” rating and set a $107.00 price target on shares of Cassava Sciences in a research note on Thursday, August 8th. HC Wainwright downgraded Cassava Sciences from a “buy” rating to a “neutral” rating and set a $116.00 price target for the company. in a research note on Tuesday.

Cassava Sciences Stock Performance

SAVA stock opened at $3.84 on Friday. The company has a market capitalization of $184.74 million, a price-to-earnings ratio of -2.78 and a beta of -0.59. Cassava Sciences, Inc. has a fifty-two week low of $3.65 and a fifty-two week high of $42.20. The stock has a fifty day moving average of $24.95 and a 200-day moving average of $22.79.

Cassava Sciences (NASDAQ:SAVA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.79. During the same period in the previous year, the firm posted ($0.61) EPS. Equities analysts predict that Cassava Sciences, Inc. will post -3.97 EPS for the current year.

Cassava Sciences Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.